Ancestry vs Health Insights - Why Most Companies Only Do One Well

If you've looked at the consumer genetic testing landscape, you've probably noticed something: the big ancestry players have added health features, and some health-focused companies have added ancestry. But there's a difference between offering both and doing both well, and that gap is wider than most company marketing suggests.

The underlying science of ancestry composition and health predisposition share a common starting point - your genotype - but diverge significantly from there. The expertise, reference data, and validation methodologies are genuinely different. Here's why.

What makes ancestry analysis hard to do well

Ancestry composition works by comparing your genotype to reference populations. The quality of that analysis depends entirely on the reference panel: how many populations are represented, how recently the reference data was collected, how well the panel captures admixed populations, and how fine-grained the geographic resolution is.

Companies that built their reputation on ancestry have typically invested years in building and curating these reference populations. They've recruited reference individuals from specific geographic communities, validated ancestral attribution through genealogical records, and refined their algorithms iteratively against millions of customer samples. The result is high geographic resolution - distinguishing, say, Scandinavian from Northwestern European rather than just lumping them as "European."

A company that adds ancestry as an afterthought, using a purchased or licensed reference panel rather than one they've developed and curated themselves, can still produce a plausible ancestry result. But the resolution will be lower, the confidence for admixed ancestry categories will be weaker, and edge cases - people with unusual ancestral mixes - will be handled less gracefully.

What makes health analysis hard to do well

Health predisposition reports face a completely different set of challenges. The science here requires deep engagement with clinical and epidemiological literature, an understanding of which findings are actionable versus merely interesting, and a responsible framework for communicating risk without creating unnecessary fear or false reassurance.

Polygenic risk scores require ongoing curation as new GWAS studies are published. A score that was state-of-the-art two years ago may be substantially outdated now. Maintaining current health reports means having a scientific team that actively monitors the literature, vets new findings, and updates the algorithm when the evidence warrants it - not just when it's convenient for the product roadmap.

There's also the regulatory and ethical dimension. Health-related findings carry clinical implications. The FDA has regulatory authority over genetic health tests sold in the United States, and the standards for evidence required to make health claims are higher than those for ancestry. Companies that took shortcuts here have faced enforcement actions and had to withdraw health features while recalibrating their approach.

Why companies end up optimizing for one

It comes down to where the founding team came from and where early resources were directed. Companies that launched as genealogy services built teams with population genetics expertise and large customer bases who were primarily interested in ancestry. Adding health features was a product expansion decision, and the health science was necessarily layered on top of existing infrastructure rather than built as a core competency from the start.

The reverse is also true. Companies that launched with a clinical genomics focus, built around CLIA-certified labs and scientific advisory boards weighted toward medical genetics, often have more rigorous health reporting but weaker ancestry resolution.

GeneLens was built from the outset to do both. Our scientific advisory board includes population geneticists who focus specifically on the reference panel methodology and medical geneticists who focus on health report curation. Those aren't combined roles. The reason is exactly the distinction this article is about: the skills required are different, and trying to use one team to cover both leads to something being done at a lower standard.

What to look for when comparing companies

For ancestry: ask how many reference populations the company uses, how recently the reference panel was updated, and whether they have specific data on populations you're interested in. A company with 10,000 reference individuals and 45 geographic regions has a fundamentally different product than one with 130,000 reference individuals and 1,500 regions.

For health: look for CLIA certification of the lab, FDA authorization or clearance for specific health tests, published methodology, and a named scientific advisory board you can research independently. Vague claims about "peer-reviewed science" without citations or named advisors are a warning sign.

And read the fine print on what's actually included. "Health insights" can mean anything from substantive polygenic risk scores with clinical-grade interpretation to a list of trait associations with weak evidence and no medical relevance. Those aren't equivalent products, regardless of how they're marketed.